정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2445 | Completed | A Study in Healthy Men to Test if Different Formulations of BI 764198 With or Without Food Influence the Amount of BI 764198 in the Blood | Healthy | Drug: BI 764198 - Formula A Drug: BI 764198 - Formula B Drug: BI 764198 - Formula C Drug: BI 764198 - Formula D |
Phase 1 | Boehringer Ingelheim | INDUSTRY | 28 | Male | 18 Years ~ 50 Years | SGS Belgium NV Research Unit Stuivenberg, Antwerpen, Belgium |
| 2444 | Completed | A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole | COVID-19 | Drug: Acalabrutinib Treatment A Drug: Acalabrutinib Treatment B Drug: Acalabrutinib Treatment C Drug: Acalabrutinib Treatment D |
Phase 1 | AstraZeneca, Parexel | INDUSTRY | 20 | All | 18 Years ~ 55 Years | Research Site, Berlin, Germany |
| 2443 | Recruiting | A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study | Covid-19 | Drug: Anakinra Prefilled Syringe Drug: Tocilizumab Prefilled Syringe Drug: Standard-of-care treatment |
Phase 2 | Karolinska University Hospital, Karolinska Institutet | OTHER | 120 | All | 18 Years | Karolinska University Hospital, Huddinge, Stockholm, Sweden |
| 2442 | Recruiting | A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults | COVID-19 | Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant Other: Placebo |
Phase 2 | Novavax, Bill and Melinda Gates Foundation | INDUSTRY | 4400 | All | 18 Years ~ 84 Years | ZA018, Bloemfontein, Free State Of South Africa, South Africa ZA003, Hillbrow, Gauteng, South Africa Site ZA001, Johannesburg, Gauteng, South Africa ZA012, Johannesburg, Gauteng, South Africa Site ZA015, Pretoria, Gauteng, South Africa ZA023, Pretoria, Gauteng, South Africa ZA019, Durban, KwaZulu-Natal, South Africa ZA020, Durban, KwaZulu-Natal, South Africa ZA021, Durban, KwaZulu-Natal, South Africa ZA024, Durban, KwaZulu-Natal, South Africa ZA007, Thabazimbi, Limpopo, South Africa ZA022, Madibeng, North-West, South Africa ZA013, Cape Town, Western Cape, South Africa ZA014, Worcester, Western Cape, South Africa |
| 2441 | Active, not recruiting | A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom | COVID-19 | Biological: SARS-CoV-2 rS/Matrix M1-Adjuvant Other: Placebo Biological: Licensed seasonal influenza vaccine |
Phase 3 | Novavax | INDUSTRY | 15000 | All | 18 Years ~ 84 Years | Belfast Health and Social Care Trust (BHSCT) (Site UK011), Belfast, Antrim, United Kingdom Synexus Midlands Clinical Research Centre (Site UK024), Edgbaston, Birmingham, United Kingdom The Royal Cornwall Hospitals NHS Trust (Site UK036), Truro, Cornwall, United Kingdom Royal Devon and Exeter Hospital (Site UK013), Exeter, Devon, United Kingdom "Maidstone Hospital - Central Research and Development Office Above Breast Care Centre - 1st Floor" (Site UK028), Maidstone, Kent, United Kingdom Queen Elizabeth University Hospital (Site UK008), Glasgow, Lanarkshire, United Kingdom Blackpool Teaching Hospitals (Site UK010), Blackpool, Lancashire, United Kingdom Salford Hospital (Site UK030), Oldham, Lancashire, United Kingdom Synexus Merseyside Clinical Research Centre (Site UK026), Waterloo, Liverpool, United Kingdom Royal Free (Site UK012), Hampstead, London, United Kingdom St. George's University Hospitals NHS Foundation Trust Clinical Research Facility (Site UK001), Tooting, London, United Kingdom North Wales Clinical Research Centre (NWCRC) (Site UK027), Wrexham, North Wales, United Kingdom Lakeside Healthcare, Lakeside Surgery (Site UK005), Corby, Northants, United Kingdom Warneford Hospital (Site UK016), Oxford, Oxfordshire, United Kingdom Aberdeen Royal Infirmary (Site UK007), Foresterhill, Aberdeen, United Kingdom Bradford Teaching Hospitals NHS Trust (Site UK018), Bradford, United Kingdom Synexus Wales Clinical Research Centre (Site UK025), Cardiff, United Kingdom Synexus Lancashire Clinical Research Centre (Site UK022), Chorley, United Kingdom Colchester Hospital (Site UK034), Colchester, United Kingdom AES - Glasgow (Site UK033), Glasgow, United Kingdom University Hartlepool Hospital (Site UK021), Hartlepool, United Kingdom Synexus Hexham Clinical Research Centre (Site UK023), Hexham, United Kingdom Royal Lancaster Infirmary (Site UK029), Lancaster, United Kingdom Research & Innovation Centre, St. James's University Hospital (Site UK019), Leeds, United Kingdom St. Thomas' Hospital (Site UK020), London, United Kingdom Chelsea & Westminster NHS Foundation Trust (Site UK006), London, United Kingdom AES - Synexus Manchester (Site UK032), Manchester, United Kingdom Norfolk and Norwich University Hospital NHS Foundation Trust, Norfolk and Norwich University Hospital (Site UK015), Norwich, United Kingdom Wansford and Kingscliffe Practice (Site UK035), Peterborough, United Kingdom AES - Synexus Thames Valley (Site UK031), Reading, United Kingdom University Hospital Southampton NHS Foundation Trust (UHS) (Site UK014), Southampton, United Kingdom Midlands Partnership NHS Foundation Trust Headquarters (Site UK017), Stafford, United Kingdom Stockport NHS Foundation Trust (Site UK009), Stockport, United Kingdom |
| 2440 | Active, not recruiting | A Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-study | Covid19 Vaccine | Biological: MVC-COV1901(S protein with adjuvant) | Phase 2 | Medigen Vaccine Biologics Corp. | INDUSTRY | 399 | All | 20 Years ~ 64 Years | Chang-Guang Memorial Hospital Lin-Kou, Taoyuan, Taiwan |
| 2439 | Active, not recruiting | A Study of a Candidate COVID-19 Vaccine (COV001) | Coronavirus | Biological: ChAdOx1 nCoV-19 Biological: MenACWY Biological: ChAdOx1 nCoV-19 full boost Biological: ChAdOx1 nCoV-19 half boost Biological: MenACWY boost Drug: Paracetamol Biological: ChAdOx1 nCoV-19 0.5mL boost Biological: ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) late vaccine (LV) Biological: ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) late vaccine two (LVT) |
Phase 2 | University of Oxford | OTHER | 1090 | All | 18 Years ~ 55 Years | University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom St Georges University Hospital NHS Foundation Trust, London, United Kingdom Imperial College Healthcare NHS Trust, London, United Kingdom CCVTM, University of Oxford, Churchill Hospital, Oxford, United Kingdom John Radcliffe Hospital, Oxford, United Kingdom |
